Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

762 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design.
Hara H, Serruys PW, O'Leary N, Gao C, Murray A, Breslin E, Garg S, Bureau C, Reiber JH, Barbato E, Aminian A, Janssens L, Rosseel L, Benit E, Campo G, Guiducci V, Casella G, Santarelli A, Franzè A, Diaz VAJ, Iñiguez A, Brugaletta S, Sabate M, Amat-Santos IJ, Amoroso G, Wykrzykowska J, von Birgelen C, Somi S, Liu T, Hofma SH, Curzen N, Trillo R, Ocaranza R, Mathur A, Smits PC, Escaned J, Baumbach A, Wijns W, Sharif F, Onuma Y; PIONEER IV trial investigator. Hara H, et al. Among authors: campo g. Am Heart J. 2022 Apr;246:32-43. doi: 10.1016/j.ahj.2021.12.018. Epub 2022 Jan 3. Am Heart J. 2022. PMID: 34990582
Safety and long-term efficacy of sirolimus eluting stent in ST-elevation acute myocardial infarction: the REAL (Registro REgionale AngiopLastiche Emilia-Romagna) registry.
Percoco G, Manari A, Guastaroba P, Campo G, Guiducci V, Aurier E, Sangiorgio P, Passerini F, Geraci G, Piovaccari G, Naldi M, Saia F, Marzocchi A; Real Investigators. Percoco G, et al. Among authors: campo g. Cardiovasc Drugs Ther. 2006 Feb;20(1):63-8. doi: 10.1007/s10557-006-6753-9. Cardiovasc Drugs Ther. 2006. PMID: 16534548
Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial.
Valgimigli M, Bolognese L, Anselmi M, Campo G, Rodriguez AE, de Cesare N, Cohen DJ, Sheiban I, Colangelo S, Pasquetto G, Hamon M, Vranckx P, Ferrario M, Prati F, Agostoni P, Malagutti P, Arcozzi C, Parrinello G, Vassanelli C, Ferrari R, Percoco G. Valgimigli M, et al. Among authors: campo g. Am Heart J. 2007 Jul;154(1):39-45. doi: 10.1016/j.ahj.2007.03.023. Am Heart J. 2007. PMID: 17584549 Clinical Trial.
ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007.
Daemen J, Simoons ML, Wijns W, Bagust A, Bos G, Bowen JM, Braunwald E, Camenzind E, Chevalier B, Dimario C, Fajadet J, Gitt A, Guagliumi G, Hillege HL, James S, Jüni P, Kastrati A, Kloth S, Kristensen SD, Krucoff M, Legrand V, Pfisterer M, Rothman M, Serruys PW, Silber S, Steg PG, Tariah I, Wallentin L, Windecker SW, Aimonetti A, Allocco D, Baczynska A, Bagust A, Berenger M, Bos G, Boam A, Bowen JM, Braunwald E, Calle JP, Camenzind E, Campo G, Carlier S, Chevalier B, Daemen J, de Schepper J, Di Bisceglie G, Dimario C, Dobbels H, Fajadet J, Farb A, Ghislain JC, Gitt A, Guagliumi G, Hellbardt S, Hillege HL, Ten Hoedt R, Isaia C, James S, de Jong P, Jüni P, Kastrati A, Klasen E, Kloth S, Kristensen SD, Krucoff M, Legrand V, Lekehal M, Lenarz L, Ni Mhullain F, Nagai H, Patteet A, Paunovic D, Pfisterer M, Potgieter A, Purdy I, Raveau-Landon C, Rothman M, Serruys PW, Silber S, Simoons ML, Steg PG, Tariah I, Ternstrom S, Van Wuytswinkel J, Waliszewski M, Wallentin L, Wijns W, Windecker SW. Daemen J, et al. Among authors: campo g. Eur Heart J. 2009 Jan;30(2):152-61. doi: 10.1093/eurheartj/ehn510. Epub 2008 Nov 26. Eur Heart J. 2009. PMID: 19036745 Free article. No abstract available.
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Valgimigli M, et al. Among authors: campo g. Circulation. 2009 Jun 30;119(25):3215-22. doi: 10.1161/CIRCULATIONAHA.108.833236. Epub 2009 Jun 15. Circulation. 2009. PMID: 19528337 Clinical Trial.
Patient selection to enhance the long-term benefit of first generation drug-eluting stents for coronary revascularisation procedures. Insights from a large multicentre registry.
Saia F, Piovaccari G, Manari A, Guastaroba P, Vignali L, Varani E, Santarelli A, Benassi A, Liso A, Campo G, Tondi S, Tarantino F, De Palma R, Marzocchi A. Saia F, et al. Among authors: campo g. EuroIntervention. 2009 May;5(1):57-66. doi: 10.4244/eijv5i1a10. EuroIntervention. 2009. PMID: 19577984
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.
Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, Colangelo S, Brugaletta S, Ferrari R, Valgimigli M; 3T/2R Investigators. Campo G, et al. J Am Coll Cardiol. 2010 Oct 26;56(18):1447-55. doi: 10.1016/j.jacc.2010.03.103. J Am Coll Cardiol. 2010. PMID: 20951320 Free article. Clinical Trial.
Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY).
Valgimigli M, Campo G, Percoco G, Monti M, Ferrari F, Tumscitz C, Zuffi A, Colombo F, Kubbajeh M, Cavazza C, Cangiano E, Tebaldi M, Minarelli M, Arcozzi C, Scalone A, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R. Valgimigli M, et al. Among authors: campo g. Am Heart J. 2010 Nov;160(5):804-11. doi: 10.1016/j.ahj.2010.07.034. Am Heart J. 2010. PMID: 21095265 Clinical Trial.
Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Garg S, Sarno G, Serruys PW, Rodriguez AE, Bolognese L, Anselmi M, De Cesare N, Colangelo S, Moreno R, Gambetti S, Monti M, Bristot L, Bressers M, Garcia-Garcia HM, Parrinello G, Campo G, Valgimigli M; STRATEGY and MULTISTRATEGY Investigators. Garg S, et al. Among authors: campo g. JACC Cardiovasc Interv. 2011 Jan;4(1):66-75. doi: 10.1016/j.jcin.2010.09.017. JACC Cardiovasc Interv. 2011. PMID: 21251631 Free article.
762 results